Potentiation of Peptide Receptor Radionuclide Therapy by the PARP Inhibitor Olaparib

Metastases expressing tumor-specific receptors can be targeted and treated by binding of radiolabeled peptides (peptide receptor radionuclide therapy or PRRT). For example, patients with metastasized somatostatin receptor-positive neuroendocrine tumors (NETs) can be treated with radiolabeled somatos...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Theranostics
Main Authors: Nonnekens, Julie, van Kranenburg, Melissa, Beerens, Cecile E.M.T., Suker, Mustafa, Doukas, Michael, van Eijck, Casper H.J., de Jong, Marion, van Gent, Dik C.
Formato: Artigo
Idioma:Inglês
Publicado em: Ivyspring International Publisher 2016
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4997239/
https://ncbi.nlm.nih.gov/pubmed/27570553
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.15311
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados